Perspective Therapeutics’ (CATX) Outperform Rating Reaffirmed at Wedbush

Wedbush restated their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a report released on Monday morning,RTT News reports. Wedbush currently has a $11.00 target price on the stock.

A number of other research firms have also commented on CATX. Royal Bank Of Canada raised shares of Perspective Therapeutics from an “outperform” rating to a “moderate buy” rating and raised their price objective for the stock from $15.00 to $16.00 in a research note on Tuesday, June 3rd. B. Riley reaffirmed a “buy” rating and issued a $12.00 price objective (up previously from $9.00) on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Finally, Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Saturday, July 12th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $12.56.

Perspective Therapeutics Stock Up 3.2%

Perspective Therapeutics stock opened at $3.59 on Monday. The company has a 50 day moving average price of $3.74 and a 200 day moving average price of $3.02. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $15.27.

Hedge Funds Weigh In On Perspective Therapeutics

Several large investors have recently bought and sold shares of CATX. ProShare Advisors LLC raised its stake in Perspective Therapeutics by 49.1% during the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after purchasing an additional 5,011 shares during the last quarter. Ground Swell Capital LLC acquired a new position in Perspective Therapeutics during the 2nd quarter valued at $56,000. Los Angeles Capital Management LLC acquired a new position in Perspective Therapeutics during the 2nd quarter valued at $61,000. Wexford Capital LP acquired a new position in Perspective Therapeutics during the 4th quarter valued at $64,000. Finally, MetLife Investment Management LLC raised its stake in Perspective Therapeutics by 40.9% during the 1st quarter. MetLife Investment Management LLC now owns 31,310 shares of the company’s stock valued at $67,000 after purchasing an additional 9,082 shares during the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.